Country: Canada
Language: English
Source: Health Canada
PANTOPRAZOLE (PANTOPRAZOLE SODIUM SESQUIHYDRATE)
TEVA CANADA LIMITED
A02BC02
PANTOPRAZOLE
40MG
POWDER FOR SOLUTION
PANTOPRAZOLE (PANTOPRAZOLE SODIUM SESQUIHYDRATE) 40MG
INTRAVENOUS
15ML
Prescription
PROTON-PUMP INHIBITORS
Active ingredient group (AIG) number: 0133229001; AHFS:
CANCELLED POST MARKET
2018-04-30
PRODUCT MONOGRAPH PR PANTOPRAZOLE FOR INJECTION Pantoprazole sodium sesquihydrate for injection 40 mg pantoprazole per vial Intravenous Use Only Sterile Lyophilized Powder H + , K + -ATPASE INHIBITOR Teva Canada Limited 30 Novopharm Court Toronto, Ontario M1B 2K9 Submission Control Number: 211084 Date of Revision: November 30, 2017 ______________________________________________________________________________ Page 2 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .......................................................... 3 SUMMARY PRODUCT INFORMATION ......................................................................... 3 INDICATIONS AND CLINICAL USE .............................................................................. 3 CONTRAINDICATIONS .................................................................................................... 3 WARNINGS AND PRECAUTIONS .................................................................................. 4 ADVERSE REACTIONS .................................................................................................... 6 DRUG INTERACTIONS .................................................................................................... 8 DOSAGE AND ADMINISTRATION .............................................................................. 10 OVERDOSAGE ................................................................................................................. 13 ACTION AND CLINICAL PHARMACOLOGY ............................................................. 13 STORAGE AND STABILITY .......................................................................................... 15 SPECIAL HANDLING INSTRUCTIONS ........................................................................ 15 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................. 15 PART II: SCIENTIFIC INFORMATION ................................................................................ 16 PHARMACEUTICAL INFORMATION ................................. Read the complete document